(Q53305308)

13 May 2018

review article

1 reference

title

[Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?]. (English)

1 reference

13 May 2018

1 reference

T Grimmer

1

1 reference

13 May 2018

A Drzezga

series ordinal

2

1 reference

13 May 2018

A Kurz

series ordinal

3

1 reference

13 May 2018

language of work or name

German

0 references

publication date

1 May 2010

1 reference

13 May 2018

published in

Der Nervenarzt

1 reference

13 May 2018

volume

81

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

602-606

1 reference

13 May 2018

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00115-010-2951-6

Biological markers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-010-2951-6

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-010-2951-6

Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-010-2951-6

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00115-010-2951-6

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

21 January 2018

1 reference

12 December 2020

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls

1 reference

12 December 2020

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

1 reference

12 December 2020

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

1 reference

12 December 2020

Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease

1 reference

12 December 2020

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease

1 reference

12 December 2020

Magnetic resonance imaging of amyloid plaques in transgenic mice

1 reference

12 December 2020

Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.

1 reference

12 December 2020

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

1 reference

12 December 2020

In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain

1 reference

12 December 2020

Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease.

1 reference

12 December 2020

Imaging beta-amyloid burden in aging and dementia.

1 reference

12 December 2020

[11C]PIB binding in Parkinson's disease dementia

1 reference

12 December 2020

Neuropathological stageing of Alzheimer-related changes

1 reference

12 December 2020

Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies

1 reference

12 December 2020

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment

1 reference

12 December 2020

Microglial activation and amyloid deposition in mild cognitive impairment: a PET study

1 reference

12 December 2020

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease

1 reference

12 December 2020

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease

1 reference

12 December 2020

PET imaging of amyloid deposition in patients with mild cognitive impairment

1 reference

12 December 2020

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

1 reference

12 December 2020

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

1 reference

12 December 2020

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

1 reference

12 December 2020

Current concepts in mild cognitive impairment

1 reference

12 December 2020

In vivo amyloid imaging with PET in frontotemporal dementia.

1 reference

12 December 2020

Amyloid imaging in mild cognitive impairment subtypes.

1 reference

12 December 2020

Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid

1 reference

12 December 2020

Current state and future directions of neurochemical biomarkers for Alzheimer's disease

1 reference

12 December 2020

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

1 reference

12 December 2020

The role of apolipoprotein E in Alzheimer's disease

1 reference

12 December 2020

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

12 December 2020

Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.

1 reference

12 December 2020

Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?

1 reference

12 December 2020

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

1 reference

12 December 2020

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis

1 reference

12 December 2020

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

1 reference

12 December 2020

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

1 reference

12 December 2020

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

1 reference

12 December 2020

10.1007/S00115-010-2951-6

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018